Who are cisplatin + capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cisplatin,fluorouracil, Carboplatin, 5FU concomitant, cisplatin and fluorouracil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cisplatin-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

cisplatin + capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

cisplatin + capecitabine (cisplatin + capecitabine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (platinum agent + antimetabolite). Area: Oncology.

phase 3 Chemotherapy combination (platinum agent + antimetabolite) DNA (cisplatin); thymidylate synthase (capecitabine) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

cisplatin + capecitabine (cisplatin + capecitabine) — AstraZeneca. Cisplatin crosslinks DNA to prevent replication while capecitabine is converted to fluorouracil to inhibit thymidylate synthase, together blocking cancer cell division and survival.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
cisplatin + capecitabine TARGET	cisplatin + capecitabine	AstraZeneca	phase 3	Chemotherapy combination (platinum agent + antimetabolite)	DNA (cisplatin); thymidylate synthase (capecitabine)
Cisplatin,fluorouracil	Cisplatin,fluorouracil	Sun Yat-sen University	phase 3	Chemotherapy combination (platinum agent + antimetabolite)	DNA (direct cross-linking and antimetabolite incorporation)
Carboplatin, 5FU concomitant	Carboplatin, 5FU concomitant	Groupe Oncologie Radiotherapie Tete et Cou	phase 3	Chemotherapy combination (platinum agent + antimetabolite)	DNA (carboplatin); thymidylate synthase (5FU)
cisplatin and fluorouracil	cisplatin and fluorouracil	Sun Yat-sen University	phase 3	Chemotherapy combination (platinum agent + antimetabolite)	DNA (cisplatin); thymidylate synthase and nucleotide metabolism (fluorouracil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (platinum agent + antimetabolite) class)

Sun Yat-sen University · 2 drugs in this class
AstraZeneca · 1 drug in this class
Groupe Oncologie Radiotherapie Tete et Cou · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cisplatin + capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab